Phase I/IIa clinical study of 4th generation BTK inhibitor HBW-3220 capsules in patients with B-cell malignancies.
Year: 2025
Type: article
Study design: Clinical Trial
Source: Journal of Clinical Oncology
Authors: Ning Lee, Yong Mao, Qingchun Liu, Huilai Zhang, Zhiming Li, Lihong Liu, Ke-Shu Zhou, Hui Zhou, Liqun Zou, Haiwen Huang, Yu Yang, Huangming Hong, Xiaobing Huang, Na Zhang, Jishi Wang, Fei Li, Jiang Li, Guanfeng Liu, Yingfu Li
Institutions: Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Sun Yat-sen University Cancer Center, Fourth Hospital of Hebei Medical University, Henan Cancer Hospital, Hunan Cancer Hospital, West China Hospital of Sichuan University, First Affiliated Hospital of Soochow University, Fujian Provincial Cancer Hospital, Sichuan Cancer Hospital, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Affiliated Hospital of Guizhou Medical University, First Affiliated Hospital of Nanchang University
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410816019